Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density.

Their objective was to determine the relationship between levels of baseline turnover before PTH therapy and short-term changes in turnover during PTH therapy and subsequent changes in areal and volumetric BMD.

Who Took Part

The abstract describes 238 women taking part.

PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.

Patients included 238 postmenopausal women with low hip or spine BMD.

Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The women were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

The researchers conducted a randomized, placebo-controlled trial at four academic centers.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Alendronate, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone and Bones and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 238 women in people with osteoporosis and bone density.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.